首页> 外文会议>Conference on Photonic Therapeutics and Diagnostics >Vascular-Targeted Photodynamic of Prostate Cancer Phase with Tookad for Recurrent Prostate Cancer Following Radiation Therapy: Initial Clinical Studies
【24h】

Vascular-Targeted Photodynamic of Prostate Cancer Phase with Tookad for Recurrent Prostate Cancer Following Radiation Therapy: Initial Clinical Studies

机译:血管靶向光学动力学的前列腺癌与携带后的前列腺癌接种疗法:初始临床研究

获取原文

摘要

We report on the first clinical application of vascular-targeted photodynamic therapy using a bacteriopheophorbide derivative, Tookad, in patients with localized prostate cancer following external beam radiation therapy. Patients received either escalating intravenous drug doses at a fixed light dose or escalated light doses at the highest photosensitizer dose. Two cylindrically diffusing fibers were placed transperineally in the prostate, along with light monitoring fibers in the prostate, urethra and rectum. Treatment response was assessed with 7-day gadolinium-enhanced Tl-weighted MRI and 6-month biopsy. Lesion formation was strongly drug and light dose-dependent, with an apparent threshold response. Early biochemical and MRI responses support the clinical potential of TOOKAD-PDT to treat locally-recurrent prostate cancer.
机译:我们在外梁放射治疗后局部前列腺癌患者中使用噬菌体靶向光动力治疗的第一次临床应用报告血管靶向光动力治疗。 在最高光敏剂剂量下接受固定的光剂量或升级的光剂量以升级静脉注射药物剂量的患者。 将两个圆柱形漫射纤维在前列腺中骨膜内置于前列腺,以及前列腺,尿道和直肠中的光照纤维。 用7天的钆增强的TL加权MRI和6个月的活组织检查评估治疗响应。 病变形成强烈的药物和光剂量依赖性,具有表观阈值应答。 早期生物化学和MRI反应支持携带PDT治疗局部复发前列腺癌的临床潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号